Recursion Pharmaceuticals (RXRX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Recursion Pharmaceuticals is set to announce its Q2 2025 earnings on August 5th, with analysts predicting a loss of ($0.34) per share and revenue of $15.38 million.
• In its last earnings report, the company missed expectations, reporting a loss of ($0.50) EPS and $14.75 million in revenue, compared to estimates of ($0.44) EPS and $18.12 million.
• Recursion Pharmaceuticals' stock has seen a 2.4% increase, trading at $5.95, with a current market capitalization of $2.42 billion.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $15.38 million for the quarter.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. Recursion Pharmaceuticals's revenue was up 7.2% on a year-over-year basis. During the same period last year, the business earned ($0.39) EPS. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Up 2.4%

Shares of RXRX traded up $0.14 on Thursday, hitting $5.95. 21,803,101 shares of the stock traded hands, compared to its average volume of 25,447,660. The company has a market capitalization of $2.42 billion, a PE ratio of -3.36 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11. The business has a 50 day simple moving average of $5.21 and a 200 day simple moving average of $5.95. Recursion Pharmaceuticals has a one year low of $3.79 and a one year high of $12.36.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Focus Partners Wealth purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at $77,000. Brighton Jones LLC lifted its stake in shares of Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after buying an additional 6,699 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock valued at $953,000 after buying an additional 12,372 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Recursion Pharmaceuticals by 627.6% during the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company's stock valued at $1,423,000 after buying an additional 232,038 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Recursion Pharmaceuticals has an average rating of "Hold" and a consensus target price of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.